Bicycle Therapeutics plc

Equities

BCYC

US0887861088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
13.34 ^USD	-1.84%		+0.23%	-4.71%

Jan. 16	European Equities Traded in the US as American Depositary Receipts Rise Thursday	MT
Jan. 14	Bicycle Therapeutics plc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 through Jan-16-2025

Bicycle Therapeutics plc Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene Amplification

December 12, 2024 at 06:30 pm EST

Bicycle Therapeutics plc announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. More detailed data from this study will be presented at a future medical meeting. Based on enrollment progress, the company plans to report dose selection and topline data for both cohorts in the second half of 2025.

More detailed data from this Study will be presented at a future Medical meeting. Based on enrollment progress. The company plans to report dose selection & topline data for both cohort in the second half of 2025".

Latest news about Bicycle Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Rise Thursday	Jan. 16	MT
Bicycle Therapeutics plc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 through Jan-16-2025	Jan. 14
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	Jan. 13	MT
Bicycle Therapeutics plc Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones	Jan. 13	CI
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Jan. 10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	Jan. 07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Flat for Week	Jan. 03	MT
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	Dec. 31	MT
European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading	Dec. 26	MT
European Equities Traded in the US as American Depositary Rise in Wednesday Trading	Dec. 18	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Dec. 16	MT
B. Riley Adjusts Price Target on Bicycle Therapeutics to $17 From $28, Keeps Neutral Rating	Dec. 16	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Dec. 13	MT
Sector Update: Health Care	Dec. 13	MT
Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump	Dec. 13	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for Week	Dec. 13	MT
Bicycle Therapeutics plc - Special Call	Dec. 13
Bicycle Therapeutics plc Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene Amplification	Dec. 12	CI
European Equities Traded in the US as American Depositary Lower in Tuesday Trading	Dec. 10	MT
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts	Dec. 10	CI
European Equities Traded in the US as American Depositary Tread Water in Friday Trading	Dec. 06	MT
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading	Nov. 27	MT
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	Nov. 20	MT
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week	Nov. 15	MT
European Equities Traded in the US as American Depositary Fall in Wednesday Trading	Nov. 13	MT

Chart Bicycle Therapeutics plc

Duration

Period

BCYC: Dynamic Chart

Company Profile

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Employees

284

Sector

Biotechnology & Medical Research

Calendar

2025-03-03 - Q4 2024 Earnings Release (Projected)

More about the company